VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IART
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IARTIntegra LifeSciences Holdings Corporation
$13.86$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksIARTFinancials

Integra LifeSciences Holdings Corporation (IART) Income Statement

30Y historyFree accessUpdated daily

Revenue growth has slowed to 2.3% year-over-year in Q3 2026 with gross margin at 51.0%, down 6.2 percentage points from Q1 2026's 57.2%, while operating margin compressed to 4.6% despite SG&A reductions of 15.5% since Q2 2024.

Income StatementBalance SheetCash FlowRatios

IART Income Statement

Annual statement

IART Income Statement

Integra LifeSciences Holdings Corporation (IART) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue1.66B1.64B1.61B1.54B1.56B1.54B1.37B1.52B1.47B1.19B992.08M882.73M928.3M836.21M830.87M780.08M732.07M682.49M654.6M550.46M419.3M277.94M229.82M185.6M112.63M93.44M64.99M42.5M17.5M14.7M13.1M
Revenue Growth %0.84%1.53%4.47%-1.03%0.99%12.43%-9.6%3.06%23.92%19.77%12.39%-4.91%11.01%0.64%6.51%6.56%7.26%4.26%18.92%31.28%50.86%20.93%23.83%64.79%20.53%43.79%52.91%142.86%19.05%12.21%28.43%
Cost of Goods Sold787.58M790.01M728.47M656.84M587.36M597.81M520.83M564.68M571.5M435.51M349.09M326.54M352.8M334.08M314.43M299.15M268.19M244.92M252.83M214.67M168.31M105.54M87.3M70.6M45.77M36.01M26.82M21.8M6.1M5.2M4.7M
COGS % of Revenue-48.31%45.23%42.61%37.71%38.76%37.97%37.21%38.81%36.65%35.19%36.99%38%39.95%37.84%38.35%36.63%35.89%38.62%39%40.14%37.97%37.98%38.04%40.64%38.54%41.26%51.29%34.86%35.37%35.88%
Gross Profit869.21M845.23M882.06M884.74M970.31M944.64M851.03M952.88M900.95M752.73M642.99M556.19M575.5M502.13M516.44M480.93M463.88M437.57M401.78M335.79M250.98M172.4M142.53M115M66.85M57.43M38.17M20.7M11.4M9.5M8.4M
Gross Margin %52.46%51.69%54.77%57.39%62.29%61.24%62.03%62.79%61.19%63.35%64.81%63.01%62%60.05%62.16%61.65%63.37%64.11%61.38%61%59.86%62.03%62.02%61.96%59.36%61.46%58.74%48.71%65.14%64.63%64.12%
Gross Profit Growth %--4.18%-0.3%-8.82%2.72%11%-10.69%5.76%19.69%17.07%15.6%-3.36%14.61%-2.77%7.38%3.68%6.01%8.91%19.65%33.79%45.58%20.96%23.93%72.02%16.41%50.45%84.4%81.58%20%13.1%25.37%
Operating Expenses234.74M776.92M853.65M773.21M731.39M747.41M699.66M859.12M789.95M707.92M527.65M476.61M509.96M459.04M442.66M426.02M365.19M339.75M354.37M268.5M192.24M116.29M117.75M75.36M45.34M43.14M56.55M33.1M25.5M28.5M17.9M
OpEx % of Revenue-47.51%53%50.16%46.95%48.46%51%56.61%53.65%59.58%53.19%53.99%54.93%54.89%53.28%54.61%49.88%49.78%54.13%48.78%45.85%41.84%51.23%40.6%40.26%46.17%87.02%77.88%145.71%193.88%136.64%
Selling, General & Admin685.25M699.7M716.98M656.64M616.32M637.45M594.53M687.6M690.75M624.1M455.63M415.76M445.97M394.25M373.11M358.13M305.06M281.1M281M225.19M157.71M98.27M99.36M59.46M40.59M32.37M43.85M22.2M15.8M20.3M9.6M
SG&A % of Revenue-42.79%44.52%42.6%39.57%41.33%43.34%45.31%46.91%52.52%45.93%47.1%48.04%47.15%44.91%45.91%41.67%41.19%42.93%40.91%37.61%35.36%43.23%32.04%36.04%34.64%67.48%52.24%90.29%138.1%73.28%
Research & Development94.44M98.97M115.38M104.19M101.19M93.05M77.38M79.57M78.04M63.45M58.16M50.9M51.6M52.09M51.01M51.45M48.11M44.28M60.49M30.66M25.73M11.96M14.12M12.81M8.3M7.99M7.52M8.7M8.4M6.4M6.3M
R&D % of Revenue-6.05%7.16%6.76%6.5%6.03%5.64%5.24%5.3%5.34%5.86%5.77%5.56%6.23%6.14%6.6%6.57%6.49%9.24%5.57%6.14%4.3%6.14%6.9%7.37%8.55%11.58%20.47%48%43.54%48.09%
Other Operating Expenses0-21.75M21.29M12.38M13.88M16.91M27.76M91.94M8.29M1.34M845K4.59M-763K-1.8M-721K16.43M12.02M14.36M12.88M12.65M8.8M6.06M4.27M3.08M-3.55M2.78M5.18M2.2M1.3M1.8M2M
Operating Income634.47M68.32M28.41M111.53M238.92M197.23M151.37M93.76M111M44.8M115.34M79.59M65.54M-3.64M73.78M54.91M98.69M97.82M47.41M67.29M58.74M56.1M24.78M39.65M19.19M14.29M-18.38M-12.4M-14.1M-19M-9.5M
Operating Margin %38.3%4.18%1.76%7.23%15.34%12.79%11.03%6.18%7.54%3.77%11.63%9.02%7.06%-0.44%8.88%7.04%13.48%14.33%7.24%12.22%14.01%20.19%10.78%21.36%17.04%15.29%-28.29%-29.18%-80.57%-129.25%-72.52%
Operating Income Growth %-140.46%-74.53%-53.32%21.14%30.3%61.44%-15.53%147.74%-61.15%44.92%21.43%1898.6%-104.94%34.36%-44.36%0.89%106.33%-29.54%14.54%4.7%126.42%-37.5%106.63%34.31%177.71%-48.25%12.06%25.79%-100%-58.33%
EBITDA769.19M220.15M169.3M235.04M357.22M317.07M267.4M203.22M221.73M133.75M188M89.54M77.94M43.37M92.32M71.34M137.87M137.51M80.56M94.33M80.22M69.33M36.37M48.69M26.35M20.54M-13.21M-10.2M-12.8M-17.2M-7.5M
EBITDA Margin %46.43%13.46%10.51%15.25%22.93%20.56%19.49%13.39%15.06%11.26%18.95%10.14%8.4%5.19%11.11%9.15%18.83%20.15%12.31%17.14%19.13%24.94%15.83%26.23%23.4%21.98%-20.32%-24%-73.14%-117.01%-57.25%
EBITDA Growth %355.32%30.03%-27.97%-34.2%12.66%18.57%31.58%-8.35%65.78%-28.86%109.97%14.88%79.73%-53.03%29.4%-48.25%0.26%70.7%-14.6%17.58%15.72%90.61%-25.3%84.79%28.26%255.55%-29.48%20.31%25.58%-129.33%-63.04%
D&A (Non-Cash Add-back)115M151.83M140.89M123.51M118.3M119.84M116.03M109.46M110.73M88.94M72.67M9.95M12.4M47.01M18.54M16.43M39.17M39.69M33.15M27.04M21.48M13.22M11.59M9.04M7.16M6.26M5.18M2.2M1.3M1.8M2M
EBIT118.78M-477.25M52.4M132.45M263.49M242.66M148.95M114.06M125.34M46.33M116.21M84.2M67.53M-6.94M74.27M56.13M100.47M96.38M48.62M67.29M58.74M56.1M24.78M39.65M21.52M14.29M-18.38M-15.21M-17.56M-19M-9.5M
Net Interest Income-81.82M-67.78M-50.59M-34.17M-37.68M-43.66M-62.28M-43.18M-61.88M-34.76M-25.78M-23.5M-21.8M-14.79M-21.03M-27.18M-18.13M-22.6M-27.97M000000000000
Interest Income14.66M18.47M20.04M17.2M11.92M6.74M9.3M10.78M2.8M255K24K13K168K4.93M1.21M465K225K631K2.11M000000000000
Interest Expense96.47M86.25M70.63M51.38M49.59M50.4M71.58M53.96M64.68M35.02M25.8M23.52M21.97M19.73M22.24M27.64M18.36M23.23M30.09M000000000000
Other Income/Expense-612.16M-631.82M-46.65M-30.46M-25.03M17.45M-57.85M-33.66M-53.59M-33.42M-24.93M-18.92M-24.88M-21.15M-21.75M-26.42M-16.58M-24.67M-16.41M-7.23M-10.44M-1M3.23M3.54M3.54M1.26M7.54M7.42M5.26M2M1.9M
Pretax Income22.31M-563.5M-18.24M81.07M213.89M214.68M93.52M60.1M57.4M11.38M90.41M60.67M42.98M-24.79M52.03M28.49M82.11M73.15M31.01M60.06M48.31M55.1M28.01M43.19M22.73M15.54M-10.85M-7.8M-12.3M-17M-7.6M
Pretax Margin %1.35%-34.46%-1.13%5.26%13.73%13.92%6.82%3.96%3.9%0.96%9.11%6.87%4.63%-2.96%6.26%3.65%11.22%10.72%4.74%10.91%11.52%19.83%12.19%23.27%20.18%16.63%-16.69%-18.35%-70.29%-115.65%-58.02%
Income Tax9.3M-47.03M-11.29M13.33M33.34M45.6M-40.37M9.9M-3.4M-53.36M15.84M53.82M8.97M-7.81M10.82M505K16.45M22.2M-3.93M26.59M18.9M17.91M10.81M16.33M-12.55M-10.86M108K-1.8M-1.8M0-2M
Effective Tax Rate %41.67%8.35%61.92%16.44%15.59%21.24%-43.17%16.48%-5.92%-468.67%17.52%88.71%20.88%31.52%20.81%1.77%20.03%30.34%-12.67%44.27%39.13%32.5%38.6%37.81%-55.23%-69.89%-1%23.08%14.63%0%26.32%
Net Income13.01M-516.47M-6.94M67.74M180.55M169.07M133.89M50.2M60.8M64.74M74.56M-3.52M34M-16.98M41.2M27.99M65.67M50.95M34.93M33.47M29.41M37.19M17.2M26.86M35.28M26.16M-11.43M-6M-12.3M-17M-7.5M
Net Margin %0.79%-31.58%-0.43%4.39%11.59%10.96%9.76%3.31%4.13%5.45%7.52%-0.4%3.66%-2.03%4.96%3.59%8.97%7.47%5.34%6.08%7.01%13.38%7.48%14.47%31.32%28%-17.58%-14.12%-70.29%-115.65%-57.25%
Net Income Growth %102.63%-7337.7%-110.25%-62.48%6.79%26.28%166.71%-17.43%-6.09%-13.17%2218.9%-110.35%300.29%-141.2%47.22%-57.38%28.88%45.86%4.37%13.82%-20.94%116.28%-35.98%-23.86%34.84%329%-90.42%51.22%27.65%-126.67%70.47%
Net Income (Continuing)13.01M-516.47M-6.94M67.74M180.55M169.07M133.89M50.2M60.8M64.74M74.56M6.85M36.3M22.03M41.2M27.99M65.67M50.95M34.93M33.47M29.41M37.19M17.2M26.86M35.28M26.41M-10.96M-5.97M-12.34M-17M-7.5M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)0.17-6.73-0.090.842.161.981.570.580.720.820.94-0.050.52-0.290.720.481.090.870.480.560.490.570.280.430.570.47-0.33-0.18-0.38-0.58-0.27
EPS Growth %102.59%-7361.2%-110.74%-61.11%9.09%26.11%170.69%-19.44%-12.2%-12.77%2074.79%-109.15%279.31%-140.28%50%-55.96%25.29%81.25%-14.29%14.29%-14.04%103.57%-34.88%-24.56%21.28%242.42%-83.33%52.63%34.48%-114.81%77.69%
EPS (Basic)--6.73-0.090.872.182.001.580.590.730.831.00-0.050.52-0.300.740.521.110.880.490.610.500.620.280.460.610.54-0.33-0.18-0.38-0.58-0.27
Diluted Shares Outstanding78.58M76.75M77.01M80.34M83.52M85.48M85.23M86.49M84.45M79.12M79.19M73.88M65.92M57.6M57.03M58.99M60.3M58.58M56.76M59.16M65.49M69.13M62.2M66.21M61.79M55.59M35.11M34.12M32.28M29.57M28.11M
Basic Shares Outstanding78.58M76.75M77.01M78.17M83M84.7M84.65M85.64M82.86M78.39M74.72M73.88M65.48M56.83M55.9M53.66M59.1M58.08M55.56M55.42M58.6M60.39M60.13M58.14M58.04M46.71M35.11M33.6M32.28M29.57M28.11M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Quality remediation suppressing margins and growth

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Growth Decelerates to Low Single Digits

Revenue growth has decelerated from 11.5% year-over-year in Q4 2024 to 2.3% in Q3 2026, with the trailing four quarters averaging approximately 1.0% versus 5.1% in the preceding four — a pattern suggesting manufacturing disruptions and Tissue Reconstruction softness may be structural rather than transitory.

The quarterly data reveals a clear step-down: 2024 delivered growth rates of 9.7%, -0.4%, and 11.5% in Q2 through Q4, while 2026 has produced 2.4%, 0.8%, and 2.3% — a decline that extends well beyond normal seasonal variation. Q3 2026 revenue of $411.2M actually contracted sequentially from Q2's $418.8M, breaking the modest recovery pattern seen in prior cycles. Combined with management's acknowledgment of a $7 million Cincinnati disruption, this trajectory may indicate share loss in Tissue Reconstruction that Specialty Surgery volume is only partially offsetting.

Gross Margin Volatility Signals Structural Instability

Gross margins swung between 49.5% and 57.2% over ten quarters, with Q3 2026 at 51.0% representing a 6.2 percentage-point decline from Q1's 57.2% — a volatility range unusual for medical device manufacturers and consistent with recurring remediation costs rather than pricing dynamics.

The 7.7 percentage-point swing between Q4 2025's trough of 49.5% and Q1 2026's peak of 57.2% suggests the margin structure is being disrupted by episodic quality remediation charges and potential inventory write-downs rather than by competitive pricing pressure alone. The more recent compression from 57.2% in Q1 to 52.5% in Q2 and 51.0% in Q3 indicates that early 2026 margin gains may be reversing as remediation costs recur. Against peers like LeMaitre at 71.5% and Hologic at 61.0%, Integra's mid-50s range implies structurally lower pricing power or higher cost-of-goods intensity inherent in biological tissue processing.

SG&A Reductions Outpaced by Gross Profit Decline

SG&A was reduced 15.5% from $195.5M in Q2 2024 to $165.3M in Q3 2026, yet operating margin compressed to 4.6% from 10.2% in Q1 2026 — indicating that overhead discipline alone cannot sustain profitability as gross profit dollars contract alongside decelerating revenue.

Despite the meaningful SG&A reduction from its mid-2024 peak, SG&A still consumed 78.7% of Q3 2026 gross profit, leaving limited room for error at a $209.9M gross profit base that itself declined from $225.9M in Q2 2024. The operating margin trajectory from 10.0% in Q3 2025 to 10.2% in Q1 2026 then down to 4.6% in both Q2 and Q3 2026 suggests that cost cuts have not kept pace with gross profit erosion. This implies the company lacks sufficient operating leverage to protect margins through a revenue deceleration phase, a structural concern for a business of this scale.

2025 Impairment-Divestiture Sequence Reshaped Baseline

The $512.7M operating loss in Q2 2025 followed by a $556.2M operating gain in Q4 2025 suggests a major impairment write-down subsequently offset by divestiture proceeds — a sequence that renders trailing twelve-month metrics unreliable and makes the post-Q4 2025 period the only analytically relevant baseline.

Notably, Q4 2025 still produced a net loss of $1.7M despite the $556.2M operating gain, implying substantial non-operating charges or tax effects fully absorbed the reported gain — a detail that warrants deeper investigation of the specific items involved. On the cleaner post-Q4 2025 baseline, operating margins have declined from 10.2% in Q1 to 4.6% in Q3, suggesting the inflection point did not establish a sustainable new profitability level. The lasting impact appears to be a combination of impaired carrying values that may pressure future depreciation and amortization, and a reduced asset base that constrains the Tissue Technologies growth engine.

Cost Discipline May Undermine Long-Term Moat

R&D expenditure declined 29.8% from $31.2M in Q4 2024 to $21.9M in Q3 2026, which alongside persistent gross margin volatility raises the question of whether near-term margin recovery is being achieved at the expense of the innovation pipeline needed to sustain collagen platform differentiation.

The recent net income recovery — $4.5M in Q2 2026 and $14.9M in Q3 2026 — appears driven primarily by the reduced SG&A base rather than structural margin improvement, as gross margins declined in each of the last two consecutive quarters. The Q3 2026 EPS of $0.19 missed consensus of $0.64 by 70.3%, demonstrating how thin the operating margin base makes earnings highly vulnerable to modest shortfalls. If quality remediation costs recur with the frequency seen in 2024-2025, and the R&D reduction delays new product launches in the regenerative segment, the market may be underpricing the risk that Integra's competitive positioning erodes faster than cost discipline can compensate.

IART — Frequently Asked Questions

Quick answers to the most common questions about buying IART stock.

What was Integra LifeSciences Holdings Corporation's (IART) revenue in 2025?

For fiscal year 2025, Integra LifeSciences Holdings Corporation (IART) reported total revenue of $1.64B. This represents a 12382.8% increase compared to $13.1M in 1996.

Is Integra LifeSciences Holdings Corporation (IART) profitable?

Integra LifeSciences Holdings Corporation (IART) reported a net loss of $516.5M for the fiscal year ending 2025.

What is Integra LifeSciences Holdings Corporation's operating profit margin?

Integra LifeSciences Holdings Corporation (IART) reported an operating income of $68.3M, resulting in an operating profit margin of 4.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Integra LifeSciences Holdings Corporation's gross profit and gross margin?

Integra LifeSciences Holdings Corporation (IART) generated $845.2M in gross profit for the year, representing a gross profit margin of 51.7%. This demonstrates the company's core pricing power and production efficiency.